BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

Group 1: Earnings Performance - BioMarin Pharmaceutical reported quarterly earnings of $1.44 per share, exceeding the Zacks Consensus Estimate of $1.03 per share, and up from $0.96 per share a year ago, representing an earnings surprise of +39.81% [1] - The company posted revenues of $825.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.72%, compared to year-ago revenues of $712.03 million [2] - Over the last four quarters, BioMarin has consistently surpassed consensus EPS and revenue estimates [2] Group 2: Stock Performance and Outlook - BioMarin shares have declined approximately 11.6% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.97 for the coming quarter and $4.26 for the current fiscal year [4][7] - The Zacks Rank for BioMarin is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which BioMarin belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially affect stock performance [5][8]